Leukemia — Chronic Myeloid (CML) Clinical Trials

About Leukemia — Chronic Myeloid (CML) trials

Chronic myeloid leukemia is defined by the Philadelphia chromosome — the BCR-ABL1 fusion arising from the t(9;22) translocation — whose constitutive kinase signaling is the target of the tyrosine kinase inhibitors (TKIs) that turned CML into a largely manageable disease. This is the original success story of targeted therapy in oncology. Diagnosis detects the BCR::ABL1 fusion and identifies the transcript type by cytogenetics, FISH, or PCR, while quantitative RT-PCR for the BCR::ABL1 transcript on the International Scale is the core assay for molecular monitoring — tracking response (major molecular response, MR4, MR4.5) and guiding TKI switches.

Front-line CML trials test first-line TKI selection — including asciminib, FDA-approved in 2024 for newly diagnosed Ph+ chronic-phase disease — alongside TKI sequencing and treatment-free remission protocols. Resistance trials are often mutation-specific: they match a patient to a TKI by their BCR-ABL1 kinase domain mutation, because the T315I gatekeeper mutation resists most inhibitors and often directs selection toward ponatinib or asciminib, while variants such as E255K, F359V, and Y253H can influence which ATP-site TKI is preferred or avoided. Asciminib, the first STAMP inhibitor — a targeted therapy that binds outside the ATP site — is studied in both front-line and post-failure settings. Blast-phase CML trials often combine TKIs with acute-leukemia chemotherapy and evaluate transplant-directed strategies, and pediatric CML trials run through cooperative-group networks separately from adult trials.

CML trial intake usually checks disease phase, TKI line history, and BCR-ABL1 mutation profile. Disease phase (chronic, accelerated, or blast) determines which trial set applies. Prior TKI exposure: most R/R trials specify which TKIs the patient has received and the reason for discontinuation (resistance, intolerance, or suboptimal response). BCR-ABL1 kinase domain mutation testing for T315I and other resistance variants is often required or strongly prioritized for later-line TKI trials. Prior allogeneic stem cell transplant matters for post-transplant trials, and performance status is commonly ECOG 0-2, though some studies are stricter.

Biomarkers tested in Leukemia — Chronic Myeloid (CML) trials

These are the molecular markers most commonly required or evaluated in Leukemia — Chronic Myeloid (CML) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.